Aarkstore.com announces, The Latest market research report is available inits vast collection:Central Nervous System (CNS)...
- A review of the Central Nervous System (CNS) Cancer products underdevelopment by companies and universities/research ins...
by Universities/Institutes 60Companies Involved in Central Nervous System (CNS) Cancer TherapeuticsDevelopment 102Genzyme ...
Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) ...
Upcoming SlideShare
Loading in...5
×

Central nervous system (cns) cancer – pipeline review, h2 2012

71

Published on

2012 | Aarkstore.com || Central nervous system (cns) cancer – pipeline review, h2 2012

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
71
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Central nervous system (cns) cancer – pipeline review, h2 2012

  1. 1. Aarkstore.com announces, The Latest market research report is available inits vast collection:Central Nervous System (CNS) Cancer – Pipeline Review, H22012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Central Nervous System (CNS) Cancer - Pipeline Review, H22012, provides an overview of the indication’s therapeutic pipeline. This reportprovides information on the therapeutic development for Central Nervous System(CNS) Cancer, complete with latest updates, and special features on late-stage anddiscontinued projects. It also reviews key players involved in the therapeuticdevelopment for Central Nervous System (CNS) Cancer. Central Nervous System(CNS) Cancer - Pipeline Review, Half Year is built using data and informationsourced from Global Markets Direct’s proprietary databases, Company/Universitywebsites, SEC filings, investor presentations and featured press releases fromcompany/university sites and industry-specific third party sources, put together byGlobal Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Central Nervous System (CNS)Cancer.
  2. 2. - A review of the Central Nervous System (CNS) Cancer products underdevelopment by companies and universities/research institutes based oninformation derived from company and industry-specific sources.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Central Nervous System (CNS) Cancer.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.Table of contents:List of Tables 8List of Figures 14Introduction 15Global Markets Direct Report Coverage 15Central Nervous System (CNS) Cancer Overview 16Therapeutics Development 17An Overview of Pipeline Products for Central Nervous System (CNS) Cancer 17Central Nervous System (CNS) Cancer Therapeutics under Development byCompanies 19Central Nervous System (CNS) Cancer Therapeutics under Investigation byUniversities/Institutes 30Late Stage Products 43Comparative Analysis 43Mid Clinical Stage Products 44Comparative Analysis 44Early Clinical Stage Products 45Comparative Analysis 45Discovery and Pre-Clinical Stage Products 46Comparative Analysis 46Central Nervous System (CNS) Cancer Therapeutics – Products under Developmentby Companies 47Central Nervous System (CNS) Cancer Therapeutics – Products under Investigation
  3. 3. by Universities/Institutes 60Companies Involved in Central Nervous System (CNS) Cancer TherapeuticsDevelopment 102Genzyme Corporation 102Boehringer Ingelheim GmbH 103F. Hoffmann-La Roche Ltd. 104List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1Multiple Myeloma (Kahlers Disease) – Pipeline Review, H2 2012Respiratory Depression – Pipeline Review, H2 2012Metastatic Cancer – Pipeline Review, H2 2012Viral Infections – Pipeline Review, H2 2012Central Nervous System (CNS) Cancer – Pipeline Review, H2 2012 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012 Diabetes – Pipeline Review, H2 2012
  4. 4. Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,H2 2012 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012 Malaria – Pipeline Review, H2 2012 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,H2 2012 Dermatitis – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: enquiry@aarkstore.com

×